Weiler Kathy Johnson sold $641K of AXGN

Weiler Kathy Johnson sold 14,150 shares of Axogen, Inc. (AXGN) at $45.30 ($0.64M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Weiler Kathy Johnson
Published Aug 11, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AXGN
Neutral
low confidence
Mentioned
$AXGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXGNNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price, and that it was executed under a Rule 10b5-1 plan; no new company fundamentals are provided.

02

Market read

Traders may briefly reassess sentiment around AXGN due to the director’s sale, but the 10b5-1 framing reduces interpretive weight.

03

What to watch

The article does not provide context on total holdings before/after beyond “0 shares,” nor does it indicate whether other insiders sold or whether there were concurrent company catalysts.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-11 after-hours; reflects sale executed 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for Axogen, Inc. (AXGN).

Company-level read

Ticker impact

$AXGNNeutralLow confidence
Context

Axogen director Weiler Kathy Johnson filed a Form 4 selling 14,150 shares at $45.2980 on 2026-08-07 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to sentiment and positioning.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale with no accompanying operational, financial, or regulatory change disclosed in the text.

Market effects

No clear sector read-through from a single routine 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Axogen, Inc.

    Company whose director insider sale is disclosed via Form 4.

  • Weiler Kathy Johnson

    Director who sold 14,150 shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AXGNMedAI 8/10

Axogen Advances Prostate Market Launch, Citing $754 Million U.S. TAM

Axogen plans to launch a prostate-market product, targeting a $754M U.S. market. The company estimates 110,000 annual prostatectomy cases with a $7,000 per-procedure price. Axogen's COAPT technique, using Avance nerve allograft, has shown 80% of patients with better-than-expected erectile function after six months. 88% of surveyed patients expressed interest in the procedure.

$AXGNMed

Axogen Inc (AXGN) (Q3 2026) Earnings Call Highlights: Revenue Jumps 26% as Breast Market

Axogen Inc (AXGN) reported a 26% revenue increase in Q3 2026, driven by a 60% surge in the Breast market. CEO Michael Dale attributed growth to expanding commercial footprint and surgeon adoption. CFO Lindsay Hartley noted normal seasonality for Q4 growth. The company plans to target high-volume centers for robotic prostatectomies and expects continued growth in breast reconstruction. Gross margins for 2027 are expected to be similar to 2026, with no significant uplift anticipated.

$AXGNHighAI 8/10

AxoGen Q3 Earnings Call Highlights

AxoGen reported 96% commercial payer coverage for Avance Nerve Graft in the U.S. and updated clinical study results. It acquired BioCircuit for $200M, adding NerveTape to its portfolio. The company raised its 2026 revenue outlook to at least $290M, with organic growth of 26%. AxoGen plans to enter the prostate nerve reconstruction market in 2027.

$AXGNHigh

AxoGen, Inc. Q3 2026 Earnings Call Summary

Axogen reported Q3 2026 revenue growth of 26.2%, driven by Avance demand. Active accounts and surgeons increased significantly. The company achieved 96% U.S. commercial coverage. Acquired BioCircuit to enter the direct repair market. Raised 2026 revenue guidance to $290M. Gross margins expected to decline in Q4 due to production adjustments. BioCircuit acquisition is expected to be accretive to revenue and EBITDA margins. Prostate nerve reconstruction market development planned for 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.